Καρδιολογική Γνώμη - Εθνικό και Καποδιστριακό Πανεπιστήμιο ...

HIV λοίμωξη και καρδιαγγειακός κίνδυνος, ο ρόλος του Παράγοντα Ενεργοποίησης Αιμοπεταλίων (PAF)1175. Grunfeld C, Delaney J, Wanke C, et al. Preclinical atherosclerosis dueto HIV infection: carotid intima-medial thickness measurements fromthe FRAM study. AIDS 2009; 23:1841-9.6. Lundgren J, Reiss P, Worm S, et al. Risk of myocardial infarctionwith exposure to specific ARV from the PI, NNRTI, and NRTI drugclasses: the DAD study. In: Abstracts of the Sixteenth Conferenceon Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract44LB. Foundation for Retrovirology and Human Health, Alexandria,VA, USA.7. Pricilla Y, Peter W. Hunt, Yuaner Wu, et al. Association of abacavirand impaired endothelial function in treated and suppressed HIV-infectedpatients. Aids 2009; 23(15):2021-2027.8. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapyand risk of cardiovascular disease in persons with HIV-1 infection:exploratory analyses from the SMART trial. Antivir Ther 2008;13:177-87.9. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI andPI exposure on the risk of myocardial infarction: a case-control studynested within FHDH ANRS CO4. In: Abstracts of the Sixteenth Conferenceon Retroviruses and Opportunistic Infections, Montreal, 2009.Abstract 43LB. Foundation for Retrovirology and Human Health, Alexandria,VA, USA.10. Durand M, Sheehy O, Baril J-G, et al. Relation between use of nucleosidereverse transcriptase inhibitors (NRTI) and risk of myocardialinfarction (MI): a nested case control study using Quebec’s publichealth insurance database (QPHID). In: Abstracts of the Fifth InternationalAIDS Society Conference on HIV Pathogenesis, Treatmentand Prevention, Cape Town, South Africa, 2009. Abstract TUPEB175.11. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir usewith risk of myocardial infarction or severe cardiovascular diseaseevents: results from ACTG A5001. In: Abstracts of the Sixteenth Conferenceon Retroviruses and Opportunistic Infections, Montreal, 2009.Abstract 721. Foundation for Retrovirology and Human Health, Alexandria,VA, USA.12. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarctionand abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsoredclinical trials in adult subjects. J Acquir ImmuneDefic Syndr 2009; 51:20-8.13. Bedimo R, Westfall A, Drechsler H, et al. Abacavir use and risk ofacute myocardial infarction and cerebrovascular disease in the HAARTera. In: Abstracts of the Fifth International AIDS Society Conferenceon HIV Pathogenesis, Treatment and Prevention, Cape Town, SouthAfrica, 2009. Abstract MOAB202.14. Cooper D, Bloch M, Humphries A, et al. Simplification with fixeddosetenofovir/emtricitabine or abacavir/lamivudine in adults withsuppressed HIV replication: the STEAL study, a randomized, openlabel,96-week, non-inferiority trial. In: Abstracts of the SixteenthConference on Retroviruses and Opportunistic Infections, Montreal,2009. Abstract 576. Foundation for Retrovirology and Human Health,Alexandria, VA, USA.15. Sabin CA, Worm SW, Weber R, et al; D:A:D Study Group. Use of nucleosidereverse transcriptase inhibitors and risk of myocardial infarctionin HIV-infected patients enrolled in the D:A:D study: a multicohortcollaboration. Lancet 2008; 26:371(9622):1417-26.16. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor.Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine asthe active component (a new class of lipid chemical mediators). Journalof Biological Chemistry 1979; 254(19):9355-9358.17. Hanahan DJ, Demopoulos CA, Liehr J, et al. Identification of plateletactivating factor isolated from rabbit basophiles as acetyl glycerylether phosphorylcholine. Journal of Biological Chemistry 1980;255(12):5514-5516.18. Pinckard RN, McManus LM, Demopoulos CA, et al. Molecular pathobiologyof acetyl glyceryl ether phosphorylcholine: evidence for thestructural and functional identity with platelet-activating factor. J ReticuloendothelSoc 1980; 28(Suppl):95s-103s.19. McManus LM, Hanahan DJ, Demopoulos CA, et al. Pathobiology ofthe intravenous infusion of acetyl glyceryl ether phosphorylcholine(AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit.J Immunology 1980; 124:2919-2924.20. Zimmerman GA, McIntyre TM, Prescott SM, et al. The platelet-activatingfactor signaling system and its regulators in syndromes ofinflammation and thrombosis. Crit Care Med 2002; 30(5Suppl):S294-301.21. Benveniste J. Platelet-activating factor, a new mediator of anaphylaxisand immune complex deposition from rabbit and human basophils.Nature 1974; 249:581-582.22. Antonopoulou S, Nomikos T. Role in inflammation and atherosclerosis(Βioactive Phospholipids), Chapter 4, 2008:85-134.23. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activatingfactor, a pleiotrophic mediator of physiological and pathological processes.Crit Rev Cl Lab Sci 2003; 40(6):643-672.24. McManus LM, Pinchard RN. PAF, a putative mediator of oral inflammation.Critical Reviews in Oral Biology and Medicine 2000; 11(2):240-258.25. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem.2002; 131(6):773-9.26. Negro Alvarez JM, Miralles Lopez JC, Ortiz Martinez JL, et al. Platelet-activatingfactor antagonists. Allergol Immunopathol 1997; 25(5):249-5827. Feuerstein G, Rabinovici R, Leor J, et al. Platelet-activating factor andcardiac diseases: therapeutic potential for PAF inhibitors. J Lipid MediatCell Signal 1997; 15(3):255-84.28. Snyder F. Platelet-activating factor and its analogs: metabolic pathwaysand related intracellular processes. Biochim Biophys Acta 1995;1254:231-49.29. Tsoupras AB, Fragopoulou E, Nomikos T, et al. Characterization ofthe de novo biosynthetic enzyme of platelet activating factor, DDTinsensitivecholinephosphotransferase, of human mesangial cells. MediatorsInflamm 2007; 2007:27683.30. Shindou H, Hishikawa D, Nakanishi H, et al. A single enzyme catalyzesboth platelet-activating factor production and membrane biogenesisof inflammatory cells. Cloning and characterization of acetyl-CoA:LY-SO-PAF acetyltransferase. J Biol Chem 2007; 282(9):6532-9.31. Stafforini DM, McIntyre TM, Carter ME, et al. Human plasma platelet-activatingfactor acetylhydrolase. Association with lipoproteinparticles and role in the degradation of platelet-activating factor. JBiol Chem 1987; 262:4215–22.32. Plaeger SF, Collins BS, Musib R. Immune Activation in the Pathogenesisof Treated Chronic HIV Disease: A Workshop Summary. AIDS ResHum Retroviruses 2012; 28(5):469-7733. Del Sorbo L, Arese M, Giraudo E, et al. Tat-induced platelet-activatingfactor synthesis contributes to the angiogenic effect of HIV-1 Tat.Eur J Immunol 2001; 31(2):376-83.34. Arese M, Ferrandi C, Primo L, et al. HIV-1 Tat protein stimulates invivo vascular permeability and lymphomononuclear cell recruitment.J Immunol 2001; 15166(2):1380-8.35. Tsoupras AB, Chini M, Tsogas N, et al. Anti-platelet-activating factoreffects of highly active antiretroviral therapy (HAART): a new insightin the drug therapy of HIV infection? AIDS Res Hum Retroviruses2008; 24(8):1079-86.36. Tsoupras AB, Chini M, Mangafas N, et al. Platelet-Activating Factorand Its Basic Metabolic Enzymes in Blood of Naive HIV-Infected Patients.Angiology 2012; 63(5):343-52.37. Chini M, Tsoupras AB, Mangafas N, et al. Effects of HAART on Platelet-ActivatingFactor Metabolism in Naive HIV-Infected Patients I:Study of the Tenofovir-DF/Emtricitabine/Efavirenz HAART RegimenAIDS Res Hum Retroviruses 2011.38. Chini M, Tsoupras AB, Mangafas N, et al. Effects of highly active antiretroviraltherapy on platelet activating factor metabolism in naive HIVinfectedpatients: ii) study of the abacavir/lamivudine/efavirenz HAARTregimen. Int J Immunopathol Pharmacol. 2012; 25(1):247-58.